Inhalopédia | Inhalers

Class
- Inhaled corticosteroid (ICS)
  Long-acting beta-2 agonist (LABA)
Active ingredient
- Fluticasone furoate
- Vilanterol (as trifenatate)
Device
- Ellipta®
Inhalers techniques and maintenance
Age
- 18 +
Typical use
- Asthma
  uncontrolled on low dose ICS
Asthma management principles
- COPD (100/25 mcg dose only)
  in addition to a LAMA, when exacerbating on dual bronchodilation (LAMA/LABA)
COPD management principles
Marketed strength
- 100/25 mcg
- 200/25 mcg
Number of doses
- 30 doses
Dose indicator
- Yes | Numerical
Usual adult dosage
- Low to medium | 100/25 mcg – 1 inh QD
  High | 200/25 mcg – 1 inh QD
ICS dosing
Usual pediatric dosage
- 12-17 years
  See adult dosage
ICS dosing
Required inspiratory flow
- > 30 - 60 L/min
  Medium-low internal resistance (R2)
Inspiratory flows
Public coverage
- MN | Open/Regular Benefit
  All provinces except MN | Restricted Benefit with criteria
Provincial coverage criteria
Advantages
- Once daily dosing
- Easy handling
- Less beta-agonists side effects (palpitations/tremors)
Disadvantages
- More dysphonia
- Lip sealing difficult for some older patients
Side effects

Product monograph

Download

Breo®